18.5. 2016 BioTurku®
Prof. Fred S. Apple joins HyTest Board
Fred S. Apple, Ph.D. is Medical Director of Clinical Laboratories at Hennepin County Medical Center in Minneapolis, MN, and Professor of Laboratory Medicine and Pathology at the University of Minnesota School of Medicine, Minnesota, USA.
Dr. Apple is one of the key opinion leaders in the field of cardiovascular disease biomarker research. His research interests have been centered in the areas of cardiac biomarkers in acute coronary syndrome and heart failure, and forensic toxicology. Dr. Apple has either authored or co-authored over 150 scientific papers and served as an Associate Editor of Clinical Chemistry for over 15 years. Dr. Apple has also been a member of the ‘National Academy of Clinical Biochemistry’ Laboratory Practice committee, the ‘Joint ESC-ACCF-AHA-WHF Global Task Force’ and the ‘Universal Definition of Myocardial Infarction’ biomarker subcommittee which established clinical and laboratory practice guidelines for the use of biomarkers for acute coronary syndromes and heart failure. Finally, he is a member of the IFCC "Task Force on Clinical Application of Cardiac Biomarkers ".
Dr. Apple and his team have been collaborating with HyTest for over a decade. This has resulted in five joint research papers having been published to date. These studies have shed light on the properties of B-type natriuretic peptides in blood and also helped in terms of designing a completely new immunoassay for this important heart failure marker. The most recent joint paper focused on IGFBP-4 fragments, which are new biomarkers that could be used for cardiovascular risk assessment. In this paper we described two novel immunoassays that allow for the detection of the IGFBP-4 fragments, something that has not been previously possible.
The long term relationship between Dr. Apple and HyTest, which is based on mutual respect, led to the proposal that Dr. Apple join the Board. “Dr. Apple is a renowned and highly respected thought leader in his field. His broad experience in cardiac diagnostics will bring important insight to our company and assist us in our aim to develop the best reagents for detecting cardiac biomarkers. He will also be able to help us better understand the needs of practicing clinicians in cardiac disease diagnostics. We are greatly honored that he accepted our invitation to join our Board of Directors” stated Dr. Maria Severina, CEO of HyTest.
Dr. Kalevi Kurkijärvi will continue as chairman and Alex Michine as a member in the HyTest Board of Directors.
HyTest manufactures monoclonal antibodies and antigens which are key components of in vitro diagnostic tests. HyTest has become the most important supplier of reagents for a number of cardiovascular diseases diagnostics areas and influenza. HyTest’s primary customers are companies that operate in the field of diagnostics and international research groups.